

Additional Information Table S1D. Study characteristics of articles included in the review investigating IGF1R expression prevalences in breast cancer, *in situ* carcinoma, benign breast disease, and normal breast tissue.

Reference	Study population			Patient and tumor characteristics				Histology						IHC						
	First author Year, Country of patient inclusion	Inclusion period	No. of invasive cancers (+other tissue)	Important selection criteria	Age(range/ SD)	Tumor size*	Histological grade		LN ⁺ (%)	Normal	Benign	In situ	invasive	IDC	ILC	Other	TMA	Cores (mm)	Antibody (manufacturer)	Obs.
					pT	0%	100%	0%	100%											
Gallardo, A.[122] 2012, Spain	ns	138	HER2+	55(31-92)	25 (10-200)	I II III		57	○	○	○	●	○	○	○	●	3	ns	24-31 (Neomarkers)	3
Fu, P.[123] 2012, Japan	2001-2009	77	-	ns	1 2/3		I/II ^b III	35	○	○	○	●	○	○	○	○			3027 (Cell Signaling)	ns
Iqbal J.[124] 2012, Singapore	ns	144	TN	53(28-88)	1 2/3		I II III	28	○	○	○	○	●	●	●	●	2	1.0	Clone 3027 (Cell Signaling)	2
Kurebayashi, J.[125] 2012, Japan	1999-2003	261	-	59(ns)	1 2/3		I II III	20	○	○	○	●	○	○	○	○			24-31 (Millipore)	1
Taromaru, G.C.[126] 2012, Brazil	2002-2008	110 (+110)	including DCIS	55(26-90)	ns	ns	ns	ns	○	○	●	○	●	○	○	○			24-31 (Pleasanton)	2
Yerushalmi, R.[127] 2012, Canada	1986-1992	2871	-	ns	1 2 3		I II III	46	○	○	○	●	○	○	○	●	ns	0.6	Sc-713 (Santa Cruz)	1
Vermeulen, J.F.[36] 2012, The Netherlands	1997-2007	462	-	60 ^a (28-88)	1 2 3		I II III	48	○	○	○	○	●	●	●	●	3	0.6	NB110-87052 (Novus)	1
Bhargava, R.[128] 2011, USA	ns	191	-	ns	ns	ns	ns	ns	○	○	○	○	●	●	●	●	2	ns	G11 (Ventana)	ns
Drury, S.C.[129] 2011, UK	1981-2004	49	recurrence	55(28-81)	20 (3-70)	I II III		23	○	○	○	●	○	○	○	●	2*3	0.6	G11 (Ventana)	2
Fu, P.[130] 2011, Japan	2001-2009	296	-	59(21-93)	1 2/3		I/II ^b III	39	○	○	○	●	○	○	○	○			Clone 3027 (Cell Signaling)	ns
Hartog, H.[131] 2011, The Netherlands	1996-2005	368	-	59(27-91)	1 2 3		I II III	46	○	○	○	○	●	○	○	●	ns	ns	24-31 (Calbiochem)	1
Peiró, G.[132] 2011, Spain	1990-2001	178	LN-, stage I-II	52 ^a (23-88)	1 2 3		I II III	0	○	○	○	○	●	●	○	●	ns	0.6	ns (Neomarkers)	2
Tamimi, R.M.[133] 2011, USA	1976-1996	0 (+493)	-	46 ^a (9)	na	na	na	na	●	●	○	○	○	○	○	●	3	0.6	24-31 (Lab Vision)	ns
Kim, J.H.[134]	2000-2006	453	-	46(23-84)	1 2		I II	42	○	○	○	●	○	○	○	●	ns	6.0	ns (Cell	ns

Shimizu, C.[152] 2004, Japan	1997-1997	210	-	53(25-83)	22 (1-140)	I II III		45	○ ○ ○ ○ ● ● ● ○	24-31 (ns)	ns		
Koda, M.[153] 2003, Poland	2000-2002	50	-	55 ^a (30-80)	ns	I II III		49	○ ○ ○ ○ ● ○ ○ ○	H-60 (Santa Cruz)	2		
Ouban, A.[154] 2003, USA	ns	8	-	63(18-93)	ns	ns		ns	○ ○ ○ ○ ● ● ○ ●	ns ns	C-20 (Santa Cruz)	2	
Happerfield, L.C.[155] 1997, UK	ns	89 (+15)	-	ns	ns	I II III		ns	● ● ○ ○ ● ● ○ ○	αIR3 (na)	ns		
Turner, B.C.[156] 1997, USA	ns	94	-	ns	19 (ns)	ns		11	○ ○ ○ ○ ● ○ ○ ○	ns (Santa Cruz)	1		

a: mean; *: mean size in mm (range or SD); b: nuclear grade; ns: not stated; na: not applicable; ○: tissue not investigated; ●: tissue investigated; ◎: both TMA and full sections investigated; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; IBC: inflammatory breast cancer; ABC: advanced breast cancer; TN: triple negative; LN: lymph node; TMA: tissue microarray PT: phyllodes tumors FA: fibroadenoma; M: distant metastasis, Obs.: number of observers evaluating staining result, +: positive; -: negative